Tag Archives: Weekly Gain

9 Homebuilders That Soared This Week

By Rick Munarriz, The Motley Fool

Filed under:

One of the hottest sectors this past week was housing. Things certainly didn’t start out that way. One of the industry’s bellwethers posted disappointing quarterly results on Monday with revenue and earnings growth falling well short of analyst expectations.

But investors hungry for a second opinion got substantially better news when D.R. Horton — the country’s largest homebuilder — posted blowout quarterly results. Revenue soared 49%, and profitability skyrocketed 173% higher.

Most indications point to a speculative market in which potential homebuyers are rushing to lock in home prices before they head even higher. The National Association of Realtors reports that the average home is on the market for just 62 days, an entire month shorter than the average of 91 days a year earlier. The association also reported that home prices rose 11.8% last month, and that’s the largest year-over-year increase since 2005.

This has all of the makings of another housing bubble, but investors didn’t care. They dove into the residential property developers last week, with several companies cranking out double-digit percentage gains.

Company

April 26

Weekly Gain

D.R. Horton

$26.66

21%

PulteGroup

$21.35

19%

Meritage Home

$49.26

19%

M/I Homes

$25.10

18%

Hovnanian Enterprises

$5.67

15%

KB Home

$23.04

13%

M.D.C. Holdings

$38.18

13%

Toll Brothers

$34.69

12%

Lennar

$42.30

11%

Source: Barron’s.

We’re not just talking about a week of gains here. Pulte , KB Home , and Hovnanian more than doubled last year. Hovnanian saw its stock soar 363% in 2012!

It probably isn’t a surprise to see luxury homebuilder Toll Brothers doing so well in this climate. High-end retailers have held up surprisingly well at this stage of the economic turnaround, so it’s not a shock to see the affluent taking advantage of historically low rates to jump on freshly constructed properties. However, Pulte, KB Home, Hovnanian, and D.R. Horton cater to mainstream homebuyers merely looking for a place to call their own after years of renting.

It may not get any easier from here, but investors probably felt that way at the end of last year. Hovnanian has given up some of last year’s gains, but most of the other developers have only padded their already impressive 2012 returns. KB Home is already trading 46% higher in 2013 after more than doubling last year.

The pent-up demand is there for new homes, but investors should be looking out for any signs that the bubble will burst. The last thing they want is to be smack-dab in the middle of a sudsy mess.

Building homes isn’t the only hot revolution
With the U.S. relying on the rest of the world for such a large percentage of our goods, many investors are ready for the end of the “made in China” era. Well, it may be here. Read all about the biggest industry disruptors since the personal computer in “3 Stocks to Own for the New Industrial Revolution.” Just click here to learn

Source: FULL ARTICLE at DailyFinance

5 of Last Week's Biggest Winners

By Rick Aristotle Munarriz, The Motley Fool

Filed under:

What’s better than momentum? Mo’ momentum. Let’s take a closer look at five of this past week’s biggest scorchers.

Company

March 1

Weekly Gain

MediciNova

$2.98

47%

MGIC Investment

$3.79

39%

MAKO Surgical

$12.75

13%

Ebix

$15.33

11%

Celldex Therapeutics

$10.26

10%

Source: Barron’s.

MediciNova was an obscure and thinly traded biotech until it received fast-track designation from the FDA for its potentially promising treatment of methamphetamine dependence on Monday afternoon. Fast-track status grants an expedited review of drugs that aim to fill an unmet medical niche or treat serious diseases. More than 6 million shares of MediciNova traded hands last week, and it’s safe to say that MediciNova will no longer be an obscure and thinly traded biotech.

MGIC soared despite posting its 10th consecutive quarterly loss on Thursday. The shares rallied on the market’s confidence that home prices in general will continue to firm, making MGIC’s dicey portfolio less risky.

MAKO Surgical also bounced back after posting uninspiring financial results. They key here is that the company behind the RIO surgical robotics system for orthopedic procedures had already braced investors for the soft showing back in January. The market was won over by its cautious outlook for the year ahead, calling for the sale of 45 to 48 new RIO systems and roughly 13,500 to 14,500 procedures for all of 2013.

Ebix bounced back after getting pounded a week earlier on a bearish report. The insurance industry software specialist rose after hosting a conference call to refute the negative claims in the report. Ebix was apparently convincing enough to gain back a good chunk of the prior week’s hit.

Celldex Therapeutics has now come through with three straight weeks featuring gains of 8% or better. Momentum continues to build after revealing positive test results for its treatment for hematopoietic stem cell transplantation last month.

Keep the good vibes coming
To learn more about a few ETFs that have great promise for delivering profits to shareholders in a recovering global economy, check out The Motley Fool’s special free report “3 ETFs Set to Soar During the Recovery.” Just click here to access it now.

The article 5 of Last Week’s Biggest Winners originally appeared on Fool.com.

Longtime Fool contributor Rick Aristotle Munarriz owns shares of Ebix. The Motley Fool recommends Ebix and MAKO Surgical and owns shares of Ebix. Try any of our Foolish newsletter services free for 30 days. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
…read more
Source: FULL ARTICLE at DailyFinance